Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.71 |
| ▸ | PGR | P06401 | 10/20 | 0.71 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.71 |
| ▸ | AR | P10275 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6555591 | 0.90 | NR3C1 (0.58) | NR3C1PGRNR3C2AR | |
| SCHEMBL5641716 | 0.89 | NR3C1 (0.59) | NR3C1PGRNR3C2AR | |
| SCHEMBL5644041 | 0.88 | NR3C1 (0.59) | NR3C1PGRNR3C2AR | |
| SCHEMBL4622424 | 0.88 | NR3C1 (0.57) | NR3C1PGRNR3C2AR | |
| SCHEMBL5644925 | 0.88 | NR3C1 (0.57) | NR3C1PGRNR3C2AR | |
| SCHEMBL4590001 | 0.86 | NR3C1 (0.55) | NR3C1PGRNR3C2AR | |
| SCHEMBL5644818 | 0.85 | NR3C1 (0.55) | NR3C1PGRNR3C2AR | |
| SCHEMBL5643383 | 0.85 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL6554282 | 0.85 | NR3C1 (0.55) | NR3C1PGRNR3C2AR | |
| SCHEMBL6554366 | 0.83 | NR3C1 (1.00) | NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | claimed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | claimed |
| US-6344454-B1 | CONTRACEPTIVE PREPARATIONS,TREATMENT OF ENDOMETRIOSIS, GYNECOLOGICAL DISORDERS,PREMENSTRUAL SYMPTOMS, MALE BIRTH CONTROL, MALE HRT AND HORMONE THERAPY AND FOR TREATING ANDROLOGICAL DISEASE AGENTS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-05 | — | — | US | claimed |
| EP-1133486-B1 | NONSTEROIDAL ANTIINFLAMMATORIES | SCHERING AG (DE) | 2004-12-22 | — | — | EP | disclosed |
| US-6323199-B1 | AROMATIC HETEROCYCLIC HYDROXY AMINES OR AMIDES FOR TREATMENT OF INFLAMMATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| EP-1133486-A2 | NONSTEROIDAL ANTIINFLAMMATORIES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-19 | — | — | EP | disclosed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| WO-2000032584-A2 | NONSTEROIDAL ANTIINFLAMMATORIES | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016365-A1 | Nonsteroidal gestagens | NR5A1, GPER1, ESR2 | NR3C1 25/4885PGR 9/4885NR3C2 32/4885 |
| US-20030203902-A1 | Nonsteroidal gestagens | GPER1, NR5A1, ESR2 | NR3C1 30/4885PGR 9/4885NR3C2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.